Because we see it day-in and day-out, we tend to overlook it. Apart antibiotics and vaccines, anti-hypertensives are the single most important therapy contributing to rising life expectancies. As such, if there is one disease to know, and know well, it's hypertension. But evaluation and management are more nuanced than simply checking an office reading and prescribing the same handful of agents. It's about understanding pulse pressures, integrating home blood pressure monitoring, and tailoring agent selection and blood pressure targets to individual patients rather than uniformly adhering to national guidelines.
I've created this free monthly e-newsletter as a non-commercial, spam-free medium to convey key aspects of the disease to other physicians. Each issue is concise, summarizing one seminal paper and underscoring one key concept. Every newsletter ends with a "clinical perspective" that will change the management of the next patient you see.
Hillel Sternlicht is a board-certified nephrologist and an ASH-designated hypertension specialist. A native Virginian, he attended the University of Virginia School of Medicine and completed his residency at the Albert Einstein College of Medicine in New York. He trained in nephrology at New York-Presbyterian/Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center. Dr Sternlicht then completed a second fellowship in hypertension under George Bakris at the University of Chicago. He has authored more than a dozen publications including editorials in The Lancet, Hypertension, and The Journal of the American College of Cardiology. He currently resides in Detroit.
privacy + disclosures
This newsletter is strictly an academic endeavor; it is self-funded. I have no conflicts of interest and will not release your email address to third parties. You will not receive spam.
